focus -WSS

focus

author：leisure time 2025-09-30 12:10:16 - browse：8335

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Medicare drug price negotiation hearing pits pharma v Biden admin

focus

knowledge

WSS

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Akili, maker of video game for ADHD, to be acquired for 34 million

Harvard's David Sinclair gets blowback over aging

What will save rural psychiatry services? Higher Medicaid payments

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Stigma and the return of syphilis

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Apple is now the first public company to be valued at $3 trillion

State of the Union pitch: Bigger Medicare drug price negotiations

BioMarin wins approval for gene therapy to treat hemophilia A

Latest bird flu infection made farmworker sicker than earlier cases

Jerome Adams on the need for new antivirals for Covid

Focused ultrasound for uterine fibroids: an uphill battle

As demand for Covid shots wanes, Moderna seeks its next success

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

BioMarin wins approval for gene therapy to treat hemophilia A

Why Talkspace is targeting Medicare, a tricky market

focus

Stem cell biologist probes earliest stages of human development

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

First over

State of the Union pitch: Bigger Medicare drug price negotiations

David Sabatini, ex

IVF doctors demand details after CooperSurgical lawsuit

focus

knowledge

leisure time

focus